Abstract: Since the start of 5G work in 3GPP in early 2016, tremendous progress has been made in both standardization and commercial deployments. 3GPP is now entering the second phase of 5G ...
California-based biotech Iovance Biotherapeutics announced today that its autologous tumor-infiltrating lymphocyte therapy lifileucel (Amtagvi) led to objective responses in 18 of the 41 patients (44% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results